Shares of Indianapolis-based Point Biopharma fell more than 11% Monday after the company announced results of a clinical trial for its lead compound that fell short of analysts’ expectations. The ...

Point Biopharma is a clinical-stage company that focuses on therapies that bind to cells to fight cancer. On Tuesday, Eli Lilly agreed to pay roughly $1.4 billion to buy the company. The deal, set at ...

Eli Lilly’s buying spree continues with the purchase of Point Biopharma for $1.4 billion, which was announced Tuesday morning. Per terms of the agreement, the pharma giant is paying $12.50 per share ...

NORTH BILLERICA, Mass. and INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (”Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, ...

Top executives and directors of Indianapolis-based Point Biopharma Global Inc. could rake in an eye-popping $212 million from their deal to sell the company to drugmaker Eli Lilly and Co. Some could ...

Eli Lilly And Co LLY agreed to acquire POINT Biopharma Global Inc PNT at $12.50 per share in cash, an aggregate of approximately $1.4 billion. POINT Biopharma is a radiopharmaceutical company with a ...

More specifically in a press release on Tuesday, Point Biopharma announced that Eli Lilly will commence a tender offer to acquire all outstanding shares of Point for $12.50 per share in cash -- a ...

INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing ...

POINT Biopharma Global Inc. has a set of radioligand therapies in various stages. It has a major deal with Lantheus. The company has a long cash runway. Looking for more investing ideas like this one?

Point Biopharma Global, Inc.’s PNT stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. LLY said it will pay $12.50 a share to acquire the Indianapolis-based cancer treatment ...

Point Biopharma focuses on oncology therapies. The company's lead therapy is PNT2002 to treat prostate cancer. Point Biopharma is a clinical-stage company that focuses on therapies that bind to cells ...